Updated:
National Cancer Institute
NCI directs the US government's $7.2B annual cancer research enterprise, funding 71 designated centers and overseeing intramural and extramural programs.
National Cancer Institute
Founded in 1937 via the National Cancer Institute Act, the NCI is the federal government's principal agency for cancer research and training. Its creation established a coordinated national response to cancer, and as the largest institute within the National Institutes of Health, it sits in Bethesda, Maryland. The institute's mandate covers basic laboratory research, clinical trials, and population science, funded entirely through federal appropriations. NCI allocates its budget through an extensive extramural funding program that supports thousands of investigators at universities, medical schools, and research institutions across the United States and select international sites. Its intramural program houses approximately 250 principal investigators on the NIH campus conducting in-house research. The institute designates and provides infrastructure support to 71 NCI-designated cancer centers — a network that includes comprehensive, clinical, and basic laboratory cancer centers — establishing the backbone of translational and clinical cancer science in the country. Its research portfolio spans drug discovery, immunotherapy, genomics, epidemiology, and implementation science. With a professional staff numbering in the thousands across divisions like Cancer Biology, Cancer Prevention, and Cancer Treatment and Diagnosis, the NCI also houses the Center for Cancer Research and the Frederick National Laboratory for Cancer Research. The institute's FY 2024 appropriation of $7.2 billion reflects continued congressional investment. In April 2024, NCI launched the Cancer Screening Research Network, a clinical trials infrastructure designed to evaluate emerging multi-cancer detection tests, signaling a systematic push to assess diagnostics at population scale. NCI's structural differentiator is its role as a federal grant-making body embedded within a research-performing institution. It simultaneously funds external science and conducts intramural discovery, operating the nation's largest system of federally funded cancer centers. This dual posture — both payer and player — distinguishes it from every foundation, pharmaceutical company, and private investor in oncology.
General information
Firm type
other
Year founded
1937
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Bethesda
Corporate office
Bethesda, MD, United States
Principals
Dr. W. Kimryn Rathmell
Director
Sector focus
Frequently asked questions
How does the National Cancer Institute distribute its research funding?
NCI distributes funding primarily through an extramural grant and contract mechanism — the majority of its budget supports investigator-initiated research at universities, medical schools, and independent research organizations across the United States and internationally. A smaller but significant portion funds the intramural research program on the NIH campus in Bethesda, where government-employed scientists conduct laboratory, clinical, and population research. The institute also provides competitive infrastructure support for its network of 71 NCI-designated cancer centers.
What is the relationship between NCI, NIH, and the broader US government?
The National Cancer Institute is the largest of the 27 institutes and centers that make up the National Institutes of Health, which is itself an agency within the US Department of Health and Human Services. Its director is appointed by the President and confirmed by the Senate, and its annual budget is determined by congressional appropriation. This federal integration means NCI operates under public oversight, with strategic priorities often shaped by both scientific opportunity and legislative mandate.
Does NCI operate its own laboratories or just fund external research?
NCI does both. Its extramural program supports thousands of external investigators through competitive grants, while its intramural program maintains roughly 250 principal investigators who conduct government-operated research on-site at NIH facilities and at the Frederick National Laboratory for Cancer Research. This dual model allows NCI to carry out long-term, high-risk projects that may not fit traditional grant cycles, alongside its role as a national funder.
What are NCI-designated cancer centers, and how many exist?
NCI-designated cancer centers are institutions that meet rigorous standards for cancer research, transdisciplinary science, and community engagement as determined by peer review. As of 2024, there are 71 designated centers across the United States, categorized as Comprehensive Cancer Centers, Clinical Cancer Centers, or Basic Laboratory Cancer Centers. Designation provides competitive access to infrastructure support grants and shapes how regional cancer research and care are organized nationally.
What investment stages or translational focus areas does NCI prioritize?
NCI funds research across the full translational spectrum — from fundamental bench science through early-stage clinical trials to population-level implementation studies. Its programs span drug discovery, genomic epidemiology, cancer immunotherapy development, and behavioral interventions. Unlike private investment funds, NCI does not target specific investment stages; it deploys capital through research project grants, cooperative agreements, and contracts reviewed through a peer-review process managed in part by the Center for Scientific Review.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: